Biography of Plenary Speakers
Robert Haim Belmaker, Israel
Wednesday, 9 June 2010, 09.00 – 09.45 h
Convention Hall BC
Individual differences and evidence based psychopharmacology
Dr. Belmaker received his BA from Harvard College in 1967 and his MD from Duke Medical School in 1971. From 1972 – 74 he was a Clinical Associate at the National Institute of Mental Health in Bethesda, MD. Since 1974 he has held positions in academic psychiatry in Israel, first at the Jerusalem Mental Health Center 1974 – 1984 and then at Ben Gurion University of the Negev 1985 to the present. Dr. Belmaker chaired the local organizing committee of the CINP meeting in Jerusalem in 1982. His research interest include bipolar disorder and second messenger mechanisms of mood stabilizer action.
He was an early pioneer in transcranial magnetic stimulation (TMS) research, receiving in
1994 a NARSAD Distinguished Investigator Award on this topic and has co-edited a book
on TMS for psychiatrists which came out in second edition in 2008 with American Psychiatric
Publishing. His 1996 paper in Nature Genetics on dopamine D-4 receptor polymorphisms and human personality was a landmark in the field and his co-edited book on “Molecular Genetics of the Human Personality” with American Psychiatric Publishing is still widely distributed. He has received the Anna Monika Prize for Research
in Depression (1983), the Ziskind-Somerfeld Prize for Senior Research in Biological
Psychiatry (1993), the ECNP Lilly Research´Award (1996), the NARSAD Falcone Award for
research in affective disorder (2000) and the Research Prize of the World Federation of Societies of Biological Psychiatry (2004). He published a review of bipolar disorder in 2004 in the New England Journal of Medicine and a review of depression in 2008 in the New England Journal of Medicine.
Dr. Belmaker has published over 400 articles and chapters and edited 18 books. He served a maximum term of 10 years as Chairman of his Department of Psychiatry and remains Associate Director of the Beersheva Mental Health Center. He sees patients every Monday in his public Bipolar Disorders Clinic and is actively involved in clinical trials as well as laboratory research. Dr. Belmaker has attended eleven CINP meetings since his first in Vienna in 1978, served on the CINP Council actively for over a decade and on the Program and Nominating Committees in the past, and is now CINP President. He has been Chairman of the Israel Society for Biological Psychiatry; serves on the Israel Ministry of
Health Clinical Trials Central Regulatory Committee (Helsinki, IRB); and is on the Board of Directors of the Israel Institute for Psychobiology. Husband of 43 years, father of six children and grandfather of four, Dr. Belmaker is an avid amateur archaeologist in Israel and scuba diver.
Nancy Y. Ip, Hong Kong
Tuesday, 8 June 2010, 13.45 – 14.30 h
Convention Hall BC
From understanding synaptic plasticity to development of cognitive enhancers
Professor Nany Ip is well known for her discoveries in the biology of neurotrophic factors, which are proteins that promote the survival, development and maintenance of neurons in the nervous system. Her research led to the identification of neurotrophic factors as potential pharmaceutical agents for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. She is also internationally recognized as a leader in elucidating the molecular signaling mechanisms at synapses, where nerve cells communicate. Given the association of synaptic dysfunction with the pathophysiology of neurodegenerative diseases, her findings provide important clues for the development of therapeutics for these disorders. As a highly accomplished researcher, Professor Ip has published over 200 scientific papers in prominent reputable journals with more than 13,000 citations, and was among the top 100 highly cited researchers in neuroscience (1993-2002), and holds 18 patents. She is the Editor-in-Chief of NeuroSignals and serves on the editorial board of international journals such as J. Neurosci., and Dev. Neurobiol. As a testament to her professional achievements, Professor Ip has received numerous awards and honors including the National Natural Science Award (China’s highest honor in the natural sciences), the L’OREAL-UNESCO for Women in Science Award (making her the first honoree in life sciences from China), and the Scientific and Technological Progress Prize of Ho Leung Ho Lee Foundation. She is an Academician of the Chinese Academy of Sciences, and a fellow of the Academy of Sciences for the Developing World. She has also been the recipient of an honorary degree of Doctor of Humane Sciences by Simmons College, the Medal of Honor by the Hong Kong SAR Government, and more recently, the Leader of the Year award in research.
Under the innovative leadership of Professor Ip, HKUST has been selected as the leading institution on “Molecular Neuroscience: Basic Research and Drug Discovery” Area of Excellence (AoE) to conduct leading edge research in neuroscience and discover drugs for the treatment of neurological disorders. Through this endeavour, the AoE team has successfully developed a unique platform whereby modern molecular approaches are combined with the knowledge and ancient traditions of Chinese herbal medicine in the search for tomorrow’s medicines.
Along with her remarkable scientific achievements, Professor Ip also works tirelessly to promote science in Hong Kong. She is a founding member of the Asia-Pacific International Molecular Biology Network (which promotes the continued advancement of molecular biology and biotechnology in the Asia Pacific Region), a board member of the Hong Kong Science and Technology Parks Corporation, and a member of the Innovation and Technology Fund Vetting Committee (biotechnology). Additionally, she served on the Board of Directors of the Hong Kong Applied Science and Technology Research Institute, and the Research Grants Council.
Professor Nancy Ip obtained her PhD in pharmacology at Harvard Medical School, and was the Senior Staff Scientist at Regeneron Pharmaceuticals Inc., New York. Since joining the Hong Kong University of Science and Technology in 1993, she has served as the Associate Dean of Science (1998-2005), Director of the Biotechnology Research Institute (1996-2008), and Head of Biochemistry (2005-2009). She is currently the Chair Professor of Biochemistry, and Director of the Molecular Neuroscience Center.
Shitij Kapur, UK
Tuesday, 8 June 2010, 09.00 – 09.45 h
Convention Hall BC
Psychosis, cognition and schizophrenia – back to the future
Dr. Shitij Kapur, MBBS, FRCPC, PhD is currently the Vice Dean (Research) and Professor at the Institute of Psychiatry, King’s College London, UK. He moved to this post in 2007 after serving as Canada Research Chair for Schizophrenia and Therapeutic Neuroscience, Chief of Research at the Centre for Addiction and Mental Health, and a Professor of Psychiatry at the University of Toronto.
He graduated from the All India Institute of Medical Sciences, did his psychiatric training at the University of Pittsburgh – where he developed an interest in the biology of schizophrenia. He subsequently completed a PhD and Fellowship at the University of Toronto and his main research interest is in the use of brain imaging and animals models to understand the basis of psychosis and its treatment. His work has shown that all antipsychotics (typical and atypical) block dopamine D2 receptors in patients, though to different degrees – and that these differences are clinically very meaningful. It has shown the consequences of too much D2 blockade and has helped move the field towards lower doses and better understanding of the basis of antipsychotic action. He has questioned the standard “delayed onset” hypothesis and by virtue of imaging and clinical studies has shown that antipsychotic start action within days – thus prompting research into new clinical designs and treatment strategies. Working with basic science colleagues Dr. Kapur has focused on how animal models can be used to derive more innovative treatments for Schizophrenia – and this work has pointed to the central importance of appropriate dosing, ‘sensitization’ and the difference between continuous and intermittent dosing in Schizophrenia. His latest work uses psychological theories, computational models, and phenomenological experience of patients and combines them into a “salience hypothesis” to provide a more holistic understanding of the experience of psychosis and the impact of antipsychotic medications. Dr. Kapur has published over a hundred and eighty papers, made dozens of presentations worldwide, served on Scientific Advisory Boards of international companies and has received numerous national and international awards, AE Bennett Award of the Society for Biological Psychiatry, Paul Janssen Award of the CINP and is a Distinguished Fellow of the American Psychiatric Association. When away from his desk Dr. Kapur is usually ferrying his young children from one activity to another or trying to perfect the ultimate ‘lamb biryani’.
Prof. C. F. Lee, Hong Kong
Sunday, 6 June 2010, 18.45 – 19.15 h
Convention Hall BC
It’s all a state of mind
Director of HKU SPACE and Chair Professor of Geotechnical Engineering at HKU. Professor Lee graduated from HKU with a Bachelor degree in Civil Engineering and then a Master degree. He received his Ph.D. from the University of Western Ontario, in the field of geotechnical engineering. He worked for Ontario Hydro in Canada, on a variety of projects that included water resources management, hydropower and nuclear power. He then served as a pro-vicechancellor of HKU between 2000 and 2008.
He is serving on various boards of community services and charitable organizations.
Jeffrey Lieberman, USA
Monday, 7 June 2010, 09.00 – 09.45 h
Convention Hall BC
Treatments for schizophrenia: Current limitations and future strategies
Jeffrey A. Lieberman, MD, is a physician and scientist who has spent his career of over 25 years caring for patients and studying the nature and treatment of mental illness. Dr. Lieberman is currently is the Lawrence E. Kolb Professor and Chairman of Psychiatry at the Columbia University College of Physicians and Surgeons and Director of the New York State Psychiatric Institute. He also holds the Lieber Chair and Directs the Lieber Center for Schizophrenia Research in the Department of Psychiatry at Columbia and serves the Psychiatrist in Chief of New York Presbyterian Hospital- Columbia University Medical Center. Dr. Lieberman received his medical degree from the George Washington School of Medicine in 1975. Following his postgraduate training in psychiatry at St. Vincent’s Hospital and Medical Center of New York Medical College, he was on the faculties of the Mount Sinai School of Medicine and Albert Einstein College of Medicine, and served as Director of Research at the Hillside Hospital of Long Island Jewish Medical Center. Prior to moving to Columbia University he was Vice Chairman for Research and Scientific Affairs in the Department of Psychiatry and Director of the Mental Health and Neuroscience Clinical Research Center at the University of North Carolina at Chapel Hill School of Medicine.
Dr. Lieberman’s research has focused on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders. In this context, his work has advanced our understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs. In terms of the latter, he served as Principal Investigator of the Clinical Antipsychotic Trials of Intervention Effectiveness Research Program (CAT IE), sponsored by the NIMH. His research has been supported by grants from the National Institutes of Health and the NARSAD, Stanley, and Mental Illness Foundations. His work has been reported in more than 400 articles in the scientific literature and he has edited or co-edited eight books, including the textbook Psychiatry, currently in its second edition; Textbook of Schizophrenia, Comprehensive Care of Schizophrenia; Psychiatric Drugs; and Ethics in Psychiatric Research: A Resource Manual on Human Subjects Protection. He also serves, or has served, as Associate Editor of the American Journal of Psychiatry, Biological Psychiatry, Neuropsychopharmacology, Acta Psychiatrica Scandinavica, Schizophrenia Research, Neuroimage, International Journal of Neuropsychopharmacology, and the Schizophrenia Bulletin. Dr. Lieberman is a member of the National Academy of Sciences Institute of Medicine and recipient of the Lieber Prize for Schizophrenia Research from NARSAD, the Adolph Meyer Award from the American Psychiatric Association, the Stanley R. Dean Award for Schizophrenia Research from the American College of Psychiatry, the APA Research Award, the APA Kempf Award for Research in Psychobiology, the APA Gralnick Award for Schizophrenia Research, the Ziskind-Somerfeld Award of the Society of Biological Psychiatry, the Ernest Strecker Award of the University of Pennsylvania, the Lilly Neuroscience Award from the Collegium Internationale Neuro-Psychopharmacologicum for Clinical Research and the Exemplary Psychiatrist Award from the National Alliance of the Mentally Ill. He is or has been a member of the advisory committee for Neuropharmacologic and Psychopharmacologic Drugs of the Food and Drug Administration, the Planning Board for the Surgeon General’s Report on Mental Health, the Committee on Research on Psychiatric Treatments of the American Psychiatric Association (APA), the APA Work Group for the Development of Schizophrenia Treatment Guidelines, the Brain Disorders and Clinical Neuroscience Review Committee, the National Advisory Mental Health Council of the National Institute of Mental Health and currently chairs the APA Council of Research. He resides with his wife and two sons in New York City.
Robin Murray, United Kingdom
Monday, 7 June 2010, 13.45 – 14.30 h
Convention Hall BC
Marijuana; from mellow to madness
Robin Murray received his medical degree from the University of Glasgow, Scotland, and trained in Internal Medicine there. He then came to study psychiatry at the Maudsley Hospital in London and has remained there ever since, apart from 1 year as MRC Fellow at NIH in Washington. He was Dean of the Institute of Psychiatry and is now Professor of Psychiatric Research there. According to ISI he is the second most widely cited psychiatric researcher in the world living outside the USA. His special interest is in the understanding and treatment of psychotic illnesses, and he looks after people with these illnesses.
Barbara Sahakian, United Kingdom
Thursday, 10 June 2010, 11.15 – 12.00 h
Convention Hall BC
The Ethics of Elective Psychopharmacology
Barbara J Sahakian is Professor of Clinical Neuropsychology at the department of Psychiatry, University of Cambridge school of Clinical Medicine and Honorary Consultant Clinic Psychologist at Addenbrooke’s Hospital. She has an international reputation in the fi elds of cognitive psychopharmacology, neuroethics, neuro psychology, neuropsychiatry and neuroimaging. She is coinventor of the CANTA B computerised neuropsychological tests, which are in use world-wide. She is probably best known for her research work on cognition and depression, cognitive enhancement using pharmacological treatments, neuroethics and early detection of Alzheimer’s disease. Indeed, she has over 300 publications covering these topics in scientific journals, including Science, Nature, Nature Neuroscience, The Lancet, British Medical Journal, Archives of General Psychiatry, American Journal of Psychiatry, Biological Psychiatry, the Journal of Neuroscience, Brain, Psychopharmacology and Psychological Medicine. Her current programme of research, funded by the Wellcome Trust and Medical research Council, investigates the neurochemical modulation of impulsive and compulsive behaviour in neuropsychiatric disorders, such as unipolar and bipolar depression and attention deficit hyperactivity disorder. This topic was the focus of her recent papers published in Science, (Chamberlain et al 2006, Chamberlain et al 2008). Professor Sahakian was one of the first searchers to suggest that attentional dysfunction in Alzheimer’s disease could be ameliorated using pharmacotherapy, such as cholinesterase inhibitors. In addition, she was early to highlight the cognitive changes in unipolar and bipolar depression, as well as their significance for functional outcome. In 2003, she was selected to lecture on this topic for the Teaching day at the annual meeting of the American College of Neuropsychopharmacology (ACNP). Most recently, she has introduced the importance of the concept of cognitive reserve to the field of Neuropsychiatry (Psychological Medicine, 2006, 36, 1053-1064). In recognition of her contribution to cognitive neuroscience, she was elected a Fellow of the Academy of Medical Sciences in 2004 and in 2005 she was awarded the donders Chair in psychopharmacology at Utrecht University (The Netherlands). Earlier this year, she gave the Deakin Innovation lectures in Melbourne, Australia and she was the firrst woman to give a plenary lecture at ECNP (Barcelona). In 2009 to 2010, she will take up the distinguished International Scholars Award at the University of Pennsylvania (USA).
Shigeto Yamawaki, Japan
Wednesday, 9 June 2010, 13.45 – 14.30
Convention Hall BC
Mood dysregulation and stabilization: Pperspectives from emotional
cognitive neuroscience
Dr. Shigeto Yamawaki is Professor and Chairman of Psychiatry and Neurosciences, Hiroshima University, Japan. He has served as Councilor (2000-2004) and secretary (2004-2006) of the CINP, and several Committee members as well as an editorial board of the IJNP. He successfully organized the CINP Asia-Pacific regional meeting in Hiroshima, 2001. He has also served as President (2006-2008) of the International College of geriatric Psychoneuropharmacology (ICgP), and as a founding President (2008-2010) of the Asian College of Neuropsychopharmacology (AsCNP). he major focus of his research is on the neurobiology and clinical psychopharmacology of mood disorders. His recent interest includes the molecular basis of early adverse life events on vulnerability for major depression, and the neuroimaging study on mood regulation using a visual emotion task and a future reward prediction task. He published more than 300 papers in the high impact international journals such as Nature Neuroscience, Biological Psychiatry, Journal of Neuroscience as well as IJNP.